Deferred treatment of localized prostate cancer in the elderly

The impact of the age and stage at the time of diagnosis on the treatment decision

E. Z. Neulander, R. C. Duncan, R. Tiguert, J. T. Posey, M. S. Soloway

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective. To assess the clinical behaviour of clinically localized prostate cancer in elderly patients monitored until progression, and the impact of clinical variables, i.e. clinical stage. Gleason score, the dynamics of prostate specific antigen (PSA) and age, on the natural history of the disease. Patients and methods. Between February 1991 and January 1998, 54 patients (mean age 76.4 years, median 77 at the time of diagnosis) with clinically localized prostate cancer who elected for watchful waiting were identified. They were monitored regularly and treatment deferred until progression. Progression was defined as local stage progression (as assessed on a digital rectal examination), biochemical progression or metastasis. All patients who progressed were offered either radiation therapy or hormonal treatment. Each clinical variable was assessed by univariate and multivariate analysis to predict disease progression. The mean follow-up was 47 months. Results. Of the 54 patients, 28 (52%) progressed; 10 had biochemical, 11 local and four biochemical and local progression, and three developed metastasis. All the patients who progressed elected to receive hormonal treatment. The mean time to progression was 35 months. Gleason score (≤ 6 and > 6), age (≤ 75 and > 75 years) and serum PSA level (≤ 10 and > 10 ng/mL) were statistically significant predictors of disease progression (P = 0.04, < 0.001 and 0.02, respectively). The clinical stage at the time of diagnosis had a borderline effect on disease progression (P = 0.06). On multivariate analysis, Gleason score and PSA level were statistically significant predictors of disease progression. Conclusion. These results suggest that the treatment of prostate cancer should not be deferred in patients aged > 75 years with a good performance status when the biopsy has a Gleason score ≥ 6 and the serum PSA level is ≥ 10 ng/mL.

Original languageEnglish
Pages (from-to)699-704
Number of pages6
JournalBJU International
Volume85
Issue number6
DOIs
StatePublished - Apr 19 2000
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Neoplasm Grading
Prostate-Specific Antigen
Disease Progression
Therapeutics
Watchful Waiting
Neoplasm Metastasis
Digital Rectal Examination
Serum
Radiotherapy
Multivariate Analysis
Biopsy

Keywords

  • Age
  • External beam radiation
  • Gleason score
  • Hormonal therapy
  • Prostate cancer
  • Serum PSA

ASJC Scopus subject areas

  • Urology

Cite this

Deferred treatment of localized prostate cancer in the elderly : The impact of the age and stage at the time of diagnosis on the treatment decision. / Neulander, E. Z.; Duncan, R. C.; Tiguert, R.; Posey, J. T.; Soloway, M. S.

In: BJU International, Vol. 85, No. 6, 19.04.2000, p. 699-704.

Research output: Contribution to journalArticle

Neulander, E. Z. ; Duncan, R. C. ; Tiguert, R. ; Posey, J. T. ; Soloway, M. S. / Deferred treatment of localized prostate cancer in the elderly : The impact of the age and stage at the time of diagnosis on the treatment decision. In: BJU International. 2000 ; Vol. 85, No. 6. pp. 699-704.
@article{35170d20b9a042699fb61f0079d755d1,
title = "Deferred treatment of localized prostate cancer in the elderly: The impact of the age and stage at the time of diagnosis on the treatment decision",
abstract = "Objective. To assess the clinical behaviour of clinically localized prostate cancer in elderly patients monitored until progression, and the impact of clinical variables, i.e. clinical stage. Gleason score, the dynamics of prostate specific antigen (PSA) and age, on the natural history of the disease. Patients and methods. Between February 1991 and January 1998, 54 patients (mean age 76.4 years, median 77 at the time of diagnosis) with clinically localized prostate cancer who elected for watchful waiting were identified. They were monitored regularly and treatment deferred until progression. Progression was defined as local stage progression (as assessed on a digital rectal examination), biochemical progression or metastasis. All patients who progressed were offered either radiation therapy or hormonal treatment. Each clinical variable was assessed by univariate and multivariate analysis to predict disease progression. The mean follow-up was 47 months. Results. Of the 54 patients, 28 (52{\%}) progressed; 10 had biochemical, 11 local and four biochemical and local progression, and three developed metastasis. All the patients who progressed elected to receive hormonal treatment. The mean time to progression was 35 months. Gleason score (≤ 6 and > 6), age (≤ 75 and > 75 years) and serum PSA level (≤ 10 and > 10 ng/mL) were statistically significant predictors of disease progression (P = 0.04, < 0.001 and 0.02, respectively). The clinical stage at the time of diagnosis had a borderline effect on disease progression (P = 0.06). On multivariate analysis, Gleason score and PSA level were statistically significant predictors of disease progression. Conclusion. These results suggest that the treatment of prostate cancer should not be deferred in patients aged > 75 years with a good performance status when the biopsy has a Gleason score ≥ 6 and the serum PSA level is ≥ 10 ng/mL.",
keywords = "Age, External beam radiation, Gleason score, Hormonal therapy, Prostate cancer, Serum PSA",
author = "Neulander, {E. Z.} and Duncan, {R. C.} and R. Tiguert and Posey, {J. T.} and Soloway, {M. S.}",
year = "2000",
month = "4",
day = "19",
doi = "10.1046/j.1464-410X.2000.00569.x",
language = "English",
volume = "85",
pages = "699--704",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Deferred treatment of localized prostate cancer in the elderly

T2 - The impact of the age and stage at the time of diagnosis on the treatment decision

AU - Neulander, E. Z.

AU - Duncan, R. C.

AU - Tiguert, R.

AU - Posey, J. T.

AU - Soloway, M. S.

PY - 2000/4/19

Y1 - 2000/4/19

N2 - Objective. To assess the clinical behaviour of clinically localized prostate cancer in elderly patients monitored until progression, and the impact of clinical variables, i.e. clinical stage. Gleason score, the dynamics of prostate specific antigen (PSA) and age, on the natural history of the disease. Patients and methods. Between February 1991 and January 1998, 54 patients (mean age 76.4 years, median 77 at the time of diagnosis) with clinically localized prostate cancer who elected for watchful waiting were identified. They were monitored regularly and treatment deferred until progression. Progression was defined as local stage progression (as assessed on a digital rectal examination), biochemical progression or metastasis. All patients who progressed were offered either radiation therapy or hormonal treatment. Each clinical variable was assessed by univariate and multivariate analysis to predict disease progression. The mean follow-up was 47 months. Results. Of the 54 patients, 28 (52%) progressed; 10 had biochemical, 11 local and four biochemical and local progression, and three developed metastasis. All the patients who progressed elected to receive hormonal treatment. The mean time to progression was 35 months. Gleason score (≤ 6 and > 6), age (≤ 75 and > 75 years) and serum PSA level (≤ 10 and > 10 ng/mL) were statistically significant predictors of disease progression (P = 0.04, < 0.001 and 0.02, respectively). The clinical stage at the time of diagnosis had a borderline effect on disease progression (P = 0.06). On multivariate analysis, Gleason score and PSA level were statistically significant predictors of disease progression. Conclusion. These results suggest that the treatment of prostate cancer should not be deferred in patients aged > 75 years with a good performance status when the biopsy has a Gleason score ≥ 6 and the serum PSA level is ≥ 10 ng/mL.

AB - Objective. To assess the clinical behaviour of clinically localized prostate cancer in elderly patients monitored until progression, and the impact of clinical variables, i.e. clinical stage. Gleason score, the dynamics of prostate specific antigen (PSA) and age, on the natural history of the disease. Patients and methods. Between February 1991 and January 1998, 54 patients (mean age 76.4 years, median 77 at the time of diagnosis) with clinically localized prostate cancer who elected for watchful waiting were identified. They were monitored regularly and treatment deferred until progression. Progression was defined as local stage progression (as assessed on a digital rectal examination), biochemical progression or metastasis. All patients who progressed were offered either radiation therapy or hormonal treatment. Each clinical variable was assessed by univariate and multivariate analysis to predict disease progression. The mean follow-up was 47 months. Results. Of the 54 patients, 28 (52%) progressed; 10 had biochemical, 11 local and four biochemical and local progression, and three developed metastasis. All the patients who progressed elected to receive hormonal treatment. The mean time to progression was 35 months. Gleason score (≤ 6 and > 6), age (≤ 75 and > 75 years) and serum PSA level (≤ 10 and > 10 ng/mL) were statistically significant predictors of disease progression (P = 0.04, < 0.001 and 0.02, respectively). The clinical stage at the time of diagnosis had a borderline effect on disease progression (P = 0.06). On multivariate analysis, Gleason score and PSA level were statistically significant predictors of disease progression. Conclusion. These results suggest that the treatment of prostate cancer should not be deferred in patients aged > 75 years with a good performance status when the biopsy has a Gleason score ≥ 6 and the serum PSA level is ≥ 10 ng/mL.

KW - Age

KW - External beam radiation

KW - Gleason score

KW - Hormonal therapy

KW - Prostate cancer

KW - Serum PSA

UR - http://www.scopus.com/inward/record.url?scp=0034109362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034109362&partnerID=8YFLogxK

U2 - 10.1046/j.1464-410X.2000.00569.x

DO - 10.1046/j.1464-410X.2000.00569.x

M3 - Article

VL - 85

SP - 699

EP - 704

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 6

ER -